The Lycopodium component of the project was $35 million capital value, excluding the building works value. Lycopodium was involved in the project through to OQ validation stages, over a period of 15 months. The total project value was over $50 million.
The manufacturing facility was fast-tracked to bring to market in a timely fashion Chemeq’s proprietary polymeric antimicrobial, Chemeq®, a replacement for antibiotics as growth promotants in the animal food production industry.
Lycopodium worked hand in hand with Chemeq in the development of a production scale Active Pharmaceutical Ingredients (API) Plant and a Formulation Plant from the laboratory scale production and testing that had been done to date. Lycopodium also worked in closely with John Holland who were contracted to undertake the construction of the manufacturing site buildings, laboratories and offices.
The manufacturing facility was designed, commissioned and validated to meet APMVA approval, and to allow for future FDA approval. The manufacturing plant was a classified Zone 2 hazardous area, and involved processing steps including reaction, polymerisation, filtration, drying, activation, blending and automated CIP systems. The plant was controlled by a GAMP compliant Distributed Control System (DCS) and included a Safety Instrumented System (SIS).
